BioNTech Good Will vs Net Working Capital Analysis

BNTX Stock

USD 87.21 0.50 0.58%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Good Will and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Good Will vs Net Working Capital

Good Will vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Good Will account and Net Working Capital. At this time, the significance of the direction appears to have very strong relationship.

The correlation between BioNTech's Good Will and Net Working Capital is 0.8. Overlapping area represents the amount of variation of Good Will that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Good Will and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Good Will of BioNTech SE are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Good Will i.e., BioNTech's Good Will and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Net Working Capital

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

BioNTech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Long Term Investments	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.76	0.82	0.85	1.0	0.98	0.62	-0.93	0.99	0.94	0.94	0.88	0.75	0.94	0.69	0.82	0.64	0.76	0.62	0.87	0.96	0.86	0.75	0.97	1.0	0.14
Short Long Term Debt Total	0.76		0.82	0.88	0.73	0.77	0.76	-0.58	0.68	0.73	0.58	0.59	0.4	0.57	0.78	0.53	0.82	0.43	0.58	0.87	0.66	0.89	0.4	0.74	0.77	0.56
Other Current Liab	0.82	0.82		0.99	0.79	0.72	0.34	-0.64	0.76	0.63	0.64	0.48	0.28	0.58	0.96	0.38	0.59	0.3	0.46	0.98	0.65	0.98	0.28	0.68	0.85	0.04
Total Current Liabilities	0.85	0.88	0.99		0.82	0.78	0.46	-0.68	0.79	0.7	0.67	0.56	0.36	0.63	0.94	0.47	0.67	0.38	0.55	1.0	0.7	1.0	0.36	0.75	0.88	0.14
Total Stockholder Equity	1.0	0.73	0.79	0.82		0.98	0.62	-0.95	1.0	0.95	0.95	0.9	0.78	0.95	0.65	0.83	0.63	0.78	0.61	0.85	0.97	0.84	0.78	0.97	0.99	0.13
Property Plant And Equipment Net	0.98	0.77	0.72	0.78	0.98		0.75	-0.93	0.98	0.98	0.94	0.94	0.82	0.96	0.58	0.88	0.69	0.82	0.64	0.8	0.98	0.8	0.82	0.99	0.97	0.27
Current Deferred Revenue	0.62	0.76	0.34	0.46	0.62	0.75		-0.53	0.6	0.8	0.55	0.79	0.72	0.63	0.27	0.79	0.69	0.74	0.62	0.46	0.67	0.49	0.72	0.77	0.59	0.74
Net Debt	-0.93	-0.58	-0.64	-0.68	-0.95	-0.93	-0.53		-0.95	-0.88	-1.0	-0.86	-0.74	-0.98	-0.44	-0.78	-0.55	-0.72	-0.49	-0.71	-0.98	-0.69	-0.74	-0.91	-0.92	-0.13
Retained Earnings	0.99	0.68	0.76	0.79	1.0	0.98	0.6	-0.95		0.95	0.96	0.91	0.8	0.97	0.61	0.85	0.59	0.8	0.62	0.82	0.97	0.81	0.8	0.97	0.99	0.09
Accounts Payable	0.94	0.73	0.63	0.7	0.95	0.98	0.8	-0.88	0.95		0.9	0.98	0.89	0.94	0.5	0.94	0.68	0.9	0.7	0.73	0.95	0.73	0.89	0.99	0.92	0.28
Cash	0.94	0.58	0.64	0.67	0.95	0.94	0.55	-1.0	0.96	0.9		0.87	0.76	0.98	0.44	0.8	0.55	0.75	0.49	0.71	0.99	0.68	0.76	0.92	0.93	0.14
Non Current Assets Total	0.88	0.59	0.48	0.56	0.9	0.94	0.79	-0.86	0.91	0.98	0.87		0.97	0.94	0.33	0.99	0.57	0.97	0.7	0.6	0.93	0.59	0.97	0.96	0.85	0.24
Non Currrent Assets Other	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97		0.87	0.15	0.99	0.41	1.0	0.69	0.41	0.82	0.41	1.0	0.87	0.71	0.15
Cash And Short Term Investments	0.94	0.57	0.58	0.63	0.95	0.96	0.63	-0.98	0.97	0.94	0.98	0.94	0.87		0.39	0.89	0.55	0.85	0.58	0.67	0.99	0.65	0.86	0.96	0.92	0.15
Net Receivables	0.69	0.78	0.96	0.94	0.65	0.58	0.27	-0.44	0.61	0.5	0.44	0.33	0.15	0.39		0.25	0.52	0.17	0.37	0.91	0.47	0.92	0.15	0.55	0.72	0.0
Good Will	0.82	0.53	0.38	0.47	0.83	0.88	0.79	-0.78	0.85	0.94	0.8	0.99	0.99	0.89	0.25		0.49	0.99	0.73	0.51	0.86	0.51	0.99	0.92	0.78	0.24
Common Stock Total Equity	0.64	0.82	0.59	0.67	0.63	0.69	0.69	-0.55	0.59	0.68	0.55	0.57	0.41	0.55	0.52	0.49		0.42	0.35	0.66	0.6	0.67	0.4	0.67	0.63	0.44
Short Term Investments	0.76	0.43	0.3	0.38	0.78	0.82	0.74	-0.72	0.8	0.9	0.75	0.97	1.0	0.85	0.17	0.99	0.42		0.72	0.43	0.81	0.43	1.0	0.87	0.71	0.16
Non Current Liabilities Total	0.62	0.58	0.46	0.55	0.61	0.64	0.62	-0.49	0.62	0.7	0.49	0.7	0.69	0.58	0.37	0.73	0.35	0.72		0.6	0.58	0.61	0.7	0.68	0.6	0.23
Inventory	0.87	0.87	0.98	1.0	0.85	0.8	0.46	-0.71	0.82	0.73	0.71	0.6	0.41	0.67	0.91	0.51	0.66	0.43	0.6		0.73	1.0	0.41	0.77	0.9	0.12
Other Current Assets	0.96	0.66	0.65	0.7	0.97	0.98	0.67	-0.98	0.97	0.95	0.99	0.93	0.82	0.99	0.47	0.86	0.6	0.81	0.58	0.73		0.71	0.82	0.97	0.94	0.23
Total Liab	0.86	0.89	0.98	1.0	0.84	0.8	0.49	-0.69	0.81	0.73	0.68	0.59	0.41	0.65	0.92	0.51	0.67	0.43	0.61	1.0	0.71		0.41	0.77	0.89	0.15
Long Term Investments	0.75	0.4	0.28	0.36	0.78	0.82	0.72	-0.74	0.8	0.89	0.76	0.97	1.0	0.86	0.15	0.99	0.4	1.0	0.7	0.41	0.82	0.41		0.87	0.71	0.14
Property Plant And Equipment Gross	0.97	0.74	0.68	0.75	0.97	0.99	0.77	-0.91	0.97	0.99	0.92	0.96	0.87	0.96	0.55	0.92	0.67	0.87	0.68	0.77	0.97	0.77	0.87		0.95	0.25
Total Current Assets	1.0	0.77	0.85	0.88	0.99	0.97	0.59	-0.92	0.99	0.92	0.93	0.85	0.71	0.92	0.72	0.78	0.63	0.71	0.6	0.9	0.94	0.89	0.71	0.95		0.12
Non Current Liabilities Other	0.14	0.56	0.04	0.14	0.13	0.27	0.74	-0.13	0.09	0.28	0.14	0.24	0.15	0.15	0.0	0.24	0.44	0.16	0.23	0.12	0.23	0.15	0.14	0.25	0.12

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Short Long Term Debt Total	68.9M	240.2M	301.5M	212.2M	219.1M	161.3M
Other Current Liab	16.4M	103.1M	3.0B	2.6B	1.3B	979.8M
Total Current Liabilities	138.1M	606.0M	3.5B	3.0B	2.1B	1.3B
Total Stockholder Equity	493.5M	1.4B	11.9B	20.1B	20.2B	21.3B
Other Liab	205.6M	97.1M	109.7M	283.9M	326.5M	166.9M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Property Plant And Equipment Net	148.1M	326.0M	520.4M	821.1M	971.6M	1.0B
Current Deferred Revenue	93.6M	391.5M	189.1M	77.1M	353.3M	371.0M
Net Debt	(450.2M)	(970.0M)	(1.4B)	(13.7B)	(11.4B)	(10.9B)
Retained Earnings	(424.8M)	(409.6M)	9.9B	18.8B	19.8B	20.8B
Accounts Payable	20.5M	102.3M	160M	204.1M	354M	371.7M
Cash	519.1M	1.2B	1.7B	13.9B	11.7B	12.2B
Non Current Assets Total	237.5M	651.7M	758.5M	1.4B	3.5B	3.7B
Non Currrent Assets Other	2K	1.0M	800K	6.5M	83.4M	87.6M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Long Term Debt	68.9M	231.0M	171.6M	176.2M	191M	116.1M
Cash And Short Term Investments	520.8M	1.3B	2.1B	14.1B	16.5B	17.4B
Net Receivables	20.2M	166.4M	12.4B	7.1B	2.3B	3.0B
Good Will	3.0M	53.7M	57.8M	61.2M	362.5M	380.6M
Common Stock Total Equity	166.8M	193.3M	232.3M	246.3M	283.3M	185.2M
Common Stock Shares Outstanding	211.5M	248.5M	259.7M	249.8M	242.7M	229.1M
Short Term Investments	1.7M	137.2M	381.6M	189.4M	4.9B	5.1B
Liabilities And Stockholders Equity	797.6M	2.3B	15.8B	23.3B	23.0B	24.2B
Non Current Liabilities Total	166.0M	340.8M	455.5M	272.9M	689.9M	378.2M
Inventory	11.7M	64.1M	502.5M	439.6M	357.7M	190.9M
Other Current Assets	1.2M	61.0M	64.9M	271.9M	280.9M	294.9M
Other Stockholder Equity	(5.5M)	1.5B	(3.8M)	(5.3M)	1.2B	1.3B
Total Liab	304.2M	946.8M	3.9B	3.2B	2.8B	1.7B
Property Plant And Equipment Gross	148.1M	326.0M	594.6M	821.1M	1.2B	1.2B
Total Current Assets	560.2M	1.7B	15.1B	21.9B	19.5B	20.5B
Accumulated Other Comprehensive Income	691.5M	25.5M	1.8B	979.3M	(984.6M)	(935.4M)
Short Term Debt	7.6M	9.1M	129.9M	36M	28.1M	32.9M
Intangible Assets	86.5M	109.8M	144.6M	158.5M	804.1M	844.3M
Common Stock	232.3M	246.3M	246.3M	248.6M	285.9M	218.0M
Property Plant Equipment	116.0M	148.1M	326.0M	520.4M	598.5M	628.4M

Pair Trading with BioNTech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.

Moving against BioNTech Stock

0.69	ELYM	Eliem Therapeutics Upward Rally	Pair Corr
0.66	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.52	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.49	HCWB	HCW Biologics	Pair Corr
0.47	ELEV	Elevation Oncology Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.

The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:

How To Invest In BioNTech

Details

Is BioNTech Stock a good investment?

Details

What is BioNTech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for BioNTech Stock analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Content Syndication Quickly integrate customizable finance content to your own investment portal

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.80)

Earnings Share

4.11

Revenue Per Share

15.873

Quarterly Revenue Growth

(0.65)

Return On Assets

0.0262

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Good Will vs Net Working Capital Analysis

Good Will vs Net Working Capital

Good Will vs Net Working Capital Correlation Analysis

Correlation Coefficient

Good Will

Net Working Capital

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Pair Trading with BioNTech

Moving against BioNTech Stock

Complementary Tools for BioNTech Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Inventory	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Retained Earnings	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Non Currrent Assets Other

Cash	- 1.0	Net Debt
Other Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Net Debt	- 0.93	Property Plant And Equipment Net